Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 41Myeloproliferative Disorders 30Polycythemia Vera 28Myelodysplastic Syndromes 15Leukemia, Myeloid, Acute 13Thrombocythemia, Essential 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasms 7Myelodysplastic-Myeloproliferative Diseases 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Hematologic Diseases 5Thrombocytosis 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Bone Marrow Diseases 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Monocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Graft vs Host Disease 2Breast Neoplasms 2Blast Crisis 2Anemia 2

Interventions

sonidegib 1ruxolitinib 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemorrhagic Disorders × ruxolitinib × Myeloid × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡